The remarkable progress in engineering and clinical development of therapeutic antibodies
in the last 40 years, after the seminal work by Köhler and Milstein, has led to the approval by …

Recent clinical trials using antibodies with low toxicity and high efficiency have raised
expectations for the development of next-generation protein therapeutics. However, the …

The interface between antibody and antigen is often depicted as a lock and key, suggesting
that an antibody surface can accommodate only one antigen. Here, we describe an antibody …

We have previously established a minimalist approach to antibody engineering by using a
phage-displayed framework to support complementarity determining region (CDR) diversity …

Antibodies developed for research and clinical applications may exhibit suboptimal stability,
expressibility, or affinity. Existing optimization strategies focus on surface mutations …

Somatic hypermutation (SHM) features in a series of 1967 immunoglobulin heavy chain
gene (IGH) rearrangements obtained from patients with chronic lymphocytic leukemia (CLL) …

Motivation: An effective docking algorithm for antibody–protein antigen complex prediction is
an important first step toward design of biologics and vaccines. We have recently developed …

Synthetic antibody libraries with restricted chemical diversity were used to explore the
intrinsic contributions of four amino acids (Tyr, Ser, Gly and Arg) to the affinity and specificity …

Highlights•Specificity is a critical attribute of drug-like monoclonal antibodies.•Antibody
specificity is compromised by excess localized charge and/or hydrophobicity.•High …

Recent studies have shown high usage of the IGHV1-69 germline immunoglobulin gene for
influenza hemagglutinin stem-directed broadly-neutralizing antibodies (HV1-69-sBnAbs) …